抗BRCA1 (MU)抗体 | Anti-BRCA1 (MU) Antibody

• 価格
• Image
• Background

価格

目次に戻る

Image

	Western Blot: BRCA1 Antibody (MU) [NB100-600] - Detection of BRCA1 using NB100-600.
	Flow Cytometry: BRCA1 Antibody (MU) [NB100-600] - Intracellular flow cytometric staining of 1 x 10^6 MCF-7 cells using BRCA1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.
	Western Blot: BRCA1 Antibody (MU) [NB100-600] - Detection of BRCA1 in MCF-7 whole cell lysate using NB100-600. 12 minute ECL exposure.

目次に戻る

Background

BRCA1 (breast cancer early-onset 1) is a tumour-suppressor gene which was originally discovered on the basis of its linkage to early-onset breast or ovarian cancer in women. BRCA1 gene encodes a protein of 1863 amino acids with three distinct regions of protein interaction: RING domain, RAD51-interaction domain and BRCT (BRCA1 C-terminus) domain. The N-terminal RING finger domain binds to several proteins, including formation of heterodimers with BARD1 (BRCA1-associated RING domain protein). Both BRCA1 and BARD1 contain the RING finger domain which is important for tumour-suppression functions. The RAD51-interaction domain is enclosed by exon 11 and is involved in DNA-DSBs repair. It also contains multiple protein-binding sites, in addition to those for RAD51/RAD50 complex. Loss of RAD51 binding increase the risk of cancer as there could be an increment in the amount of damaged DNA. The C-terminus of BRCA1 contains an acidic domain that functions as a transcriptional activation domain and this domain contains a tandem repeat of approximately 95 amino acids called BRCT. This domain is also found in proteins such as BARD1 which is involved in cell-cycle control and DNA repair. BRCA1 has been implicated in diverse cancer-related activities, including roles in cell-cycle progression, DNA repair, DNA damage-responsive cell-cycle checkpoints, transcription regulation, ubiquitination, chromosome remodelling and apoptosis. Defects in BRCA1 are a cause of susceptibility to breast cancer, familial breast-ovarian cancer type 1 (BROVCA1), ovarian cancer, and pancreatic cancer type 4 (PNCA4).

目次に戻る